Introduction
Although there is marked improvement in the life expectancy of patients with sickle cell anemia (SCA), this disease continues to be associated with high morbidity and mortality at a young age. The cascade of events starts with the polymerization of Hb-S with the sickling of the RBCs, followed by occlusion of small, as well as larger, vessels due to the adherence of the sickle cells to the vascular endothelium. As a consequence, pain crises, stroke, acute chest syndrome and multi-organ failure are the most frequent complications that impair quality of life and survival. 1 The correct use of hydroxyurea and transfusional regimens can ameliorate these complications, but allogeneic cellular gene therapy, through hematopoietic SCT (HSCT), is the only radical cure for the genetic defect. In this case, the HSC functions as a cellular vector for the normal gene into the hemopoietic system, which is replaced after transplantation with the donor cells.
In 1981, HSCT was introduced as the only approach to cure young thalassemic patients. 2, 3 There were many years of conflict in the scientific community, which was reluctant to accept this treatment for thalassemia; today, BMT is accepted worldwide as a treatment for thalassemic patients. Almost all the transplant centers in the world now report an increasing number of ex-thalassemics living a normal life after transplant. 4 Now, debate is arising about treating SCA with HSCT. The solution involves considering morbidity and mortality as one judgment; it is misleading to consider morbidity separately from mortality in SCA. In this study, we report in detail the results obtained in 11 patients with SCA consecutively transplanted at our center in Rome since 2004.
Methods
At the Mediterranean Institute of Hematology in Rome, all patients who had sickle cell disease (SCD) and an HLAmatched family donor were eligible for this study. The institutional review board approved the treatment protocol, and all parents or patients provided written informed consent in accordance with the Declaration of Helsinki. Table 1 . Five patients had a splenectomy before transplantation. Six patients were on chronic RBC transfusions due to anemia, whereas in the remaining five patients the indication for chronic transfusion was a previous stroke, frequent vaso-occlusive crisis and acute chest syndrome. Seven patients had recurrent, painful vaso-occlusive crisis, four had acute chest syndrome and one patient each had avascular bone necrosis or hemorrhagic stroke before transplantation.
Characteristics of the patients

Transplantation procedure
The conditioning regimens used are shown in Table 1 . Five patients received pre-conditioning cytoreductive/immunosuppressive chemotherapy with hydroxyurea, azathioprine and fludarabine as described elsewhere. 4 All but one patients were prepared for the transplant with BU, CY and antithymocyte globulin. They received CYA, low-dose methylprednisolone, and a short course of MTX as GVHD prophylaxis. Patients received BM grafts (n ¼ 10) or PBSC (n ¼ 1) from HLA-matched, related donors at 36 h after the last dose of CY. The median number of total nucleated cells infused was 4.1 Â 10 8 /kg (min 2.7, max 7.0) and the median number of CD34 cells was 7.1 Â 10 6 /kg (min 5.2, max 12.9). The diagnosis and degree of acute and chronic GVHD were assessed according to standard criteria. Patients were given prophylactic broad-spectrum antibiotics and antifungal drugs until the neutrophil level exceeded 1.0 Â 10 9 /L. They also received acyclovir as a herpes virus prophylaxis and trimethoprim/sulfamethoxazole as a Pneumocystis jiroveci prophylaxis. Patients were monitored weekly for the presence of EBV, CMV, Adenovirus and BK virus in the blood and/or urine using sensitive reverse-transcriptase PCR, from before conditioning until at least 100 days post transplant. CMV antigenemia monitoring was carried out twice weekly during hematological recovery.
Assessment of chimerism
The first chimerism analysis was conducted on BM samples obtained 20 days after transplant to determine the percentage of donor/recipient DNA using PCR-based analysis of STRs. Subsequently, at 60, 90, 180 and 365 days post-transplant, lineage-specific chimerism analysis was carried out by PCR using fluorescent primers flanking a single informative STR (Profiler Plus Applera, Foster City, CA, USA) previously identified to be polymorphic between the patient and donor. In sex-mismatched donor/ recipient pairs, dual-color FISH was also performed according to standard procedures with commercially available probes specific for the centromeric and heterochromatic regions of the X and Y chromosomes, respectively.
Statistical analysis
The probabilities of survival, SCA-free survival, rejection and mortality were calculated using the Kaplan-Meier estimator. 5 
Results
Engraftment
The median time to neutrophil recovery (ANC X500 Â 10 9 /L) was 16 days (range, 12-21 days) and median time to a platelet count X20 Â 10 9 /L was 18 days (range, 8-22 days). All patients had sustained engraftment with donor chimerism of 100%, except for the patient UPN 57, who showed persistent mixed chimerism with 25% of donor cells (Table 1) . This patient had a progressive decrease in donor chimerism until 25%, starting 2 months after transplantation. She had stable mixed chimerism for more than 4 years without SCD-related events and was transfusion independent. All the remaining patients had full donor chimerism in lymphoid and myeloid lineages.
Acute and chronic GVHD Seven patients developed grade 2 acute GVHD. The only patient who developed grade 3 GVHD had received a PBSCT. All the patients responded promptly to the steroid treatment given to control the acute GVHD. Four out of 11 patients had mild skin chronic GVHD that resolved completely following steroid use. 
Toxic and infectious complications
Three patients had CSA-related neurotoxicity with seizures, which required switching to Tacrolimus (FK-500). No other significant toxic complications were observed in these patients. Nine patients had positive serology for CMV at the time of transplantation and all of them showed asymptomatic CMV reactivation, which was successfully treated with pre-emptive ganciclovir. Six patients developed BK virus-related grade 2 hemorrhagic cystitis. One patient had a bacterial infection, which was successfully treated with antibiotics.
Survival
Out of 11, 10 patients survived without sickle cell disease, with Lansky/Karnofsky scores of 100. Median follow-up for survivors was 43 months (range, 12-68 months). One patient died at 1 year after transplantation in her home country; she was on tapering immunosuppressive treatment for chronic skin GVHD and died of pneumonia. The probability of survival, SCA-free survival and TRM at 5 years after transplant was 90, 90 and 10%, respectively ( Figure 1 ). After transplantation, none of the patients had complications typical of SCA, such as pains, stroke or acute chest syndrome.
Discussion
Numerous studies on HSCT in SCA report a disease-free survival ranging between 80 and 90%; 5-10 yet, there is not a large acceptance of HSCT as a radical cure for SCA. Consequently, there is an effort to categorize the risk of transplantation for these patients, as was carried out for thalassemic patients. The timing of transplantation is more problematic in patients with SCA compared with those with thalassemia, where there is great phenotypic similarity in patients of the same age. Clinically, there are large polymorphisms in SCA, which is a progressive disease. The Hb-S, is constantly at high risk of polymerization at any time after birth, after the physiological decrease of the F Hb that reduces the polymerization of the S Hb. With increasing risk of micro and macro embololism with occlusion of blood vessels, painful crises, silent or overt stroke, multiorgan damage, particularly acute chest syndrome, also the morbidity and the mortality are increasing despite the adoption of a regimen of regular blood transfusions. Allogeneic cellular gene therapy involves replacement of the defective hemopoietic system with an allogeneic HSC, which functions as a cellular vector for the normal gene-regulating globin synthesis. As in thalassemia, this procedure is the only radical cure for patients with SCA.
In 1981, BMT was recognized for the first time as the only approach to cure young thalassemic patients. Until then, treatment of these patients aimed to correct the anemia was based on RBC transfusions and chelation of the iron overloading the organs due to the life-long transfusion dependency of the patients. Now, there is debate about HSCT as a curative treatment for SCA. In this study, we report the results obtained after using a preparative regimen for the transplant similar to that used in thalassemia, with the addition of anti-thymocyte globulin. We prefer this regimen based on full dosages of BU and CY; in our experience with thalassemia, any reduction of these two drugs has been followed by an increased rate of rejection and return of the autologous hemopoietic system. We would expect the same result in SCA. We think allogeneic cellular gene therapy, through HSCT, should be offered to all SCA patients who have experienced frequent pain crises, silent stroke, and to all who reach the need of a regular blood-cell transfusion treatment, when an HLA-identical family member is available, as the 'benign' SCA phenotype is either very rare or does not exist, especially in the African SCA. Allogeneic cellular gene therapy after HSCT should be considered early in the course of this disease that inevitably becomes more severe with time.
As in many other centers that specialize in transplantation for hemoglobinopathies, we receive patients with SCA from their original medical institutions where they were followed since birth. The scientists from those institutions are the real experts on the dynamics of this clinically polymorphic and terrible disease. The experiences of the transplant centers only offer the rationale for considering HSCT as a radical cure for SCA patients, with an HLAidentical family member. This single-center report highlights the role of HSCT as the allogeneic cellular gene therapy for hemoglobinopathies, such as thalassemia and SCA.
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